INVEGA TRINZA

Paliperidone palmitate (PP), sold under the brand names Invega Sustenna, Xeplion, Shansida, Erzofri and Psokadron for the once‑monthly formulation, and as Invega Trinza/Trevicta (three‑monthly) and Invega Hafyera/Byannli (six‑monthly), is a long-acting injectable atypical antipsychotic of the benzisoxazole class, used in the treatment of schizophrenia and schizoaffective disorder. The original product was developed by Janssen Pharmaceuticals, Inc., which continues to manufacture most of the branded versions worldwide. It is an antipsychotic ester – specifically the palmitate ester of paliperidone – and acts as a long-lasting form of paliperidone. Paliperidone palmitate is formulated as an aqueous suspension, has a strong smell similar to alcohol, and is administered by intramuscular injection into deltoid or gluteal muscle once every 1, 3, or 6 months depending on the formulation. A formulation for injection once every 6 months is also pending regulatory approval as of September 2021.